Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
283 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07844811 | Early Redox Biomarker Changes After Stellate Ganglion Block in Traumatic Brain Injury | completed | — | 20 | University Medical Centre LjubljanaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer(KontRASt-02) | active not recruiting | Phase 3 | 95 | Novartis PharmaceuticalsINDUSTRY | 25 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT07837245 | Pilot Study of the Expansion of the DORA Breast Cancer Screening Programme | enrolling by invitation | N/A | 2,150 | Institute of Oncology LjubljanaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | active not recruiting | Phase 3 | 1,050 | Hoffmann-La RocheINDUSTRY | 37 | Sep 14, 2026 | clinicaltrials |
| NCT06727227 | Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer(EXPLORE) | recruiting | — | 138 | AstraZenecaINDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 | clinicaltrials |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | terminated | Phase 3 | 595 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 | clinicaltrials |
| NCT01746225 | Schedules of Nab-Paclitaxel in Metastatic Breast Cancer(SNAP) | completed | Phase 2 | 258 | ETOP IBCSG Partners FoundationNETWORK | 6 | Sep 2, 2026 | clinicaltrials |
| NCT00781612 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | active not recruiting | Phase 2 | 378 | Genentech, Inc.INDUSTRY | 35 | Aug 28, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma(RAVINA) | terminated | Phase 2 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 20, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT07716579 | Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment | completed | N/A | 12 | Institute of Oncology LjubljanaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07761871 | Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy(MEL-FIT-IO) | recruiting | N/A | 40 | Institute of Oncology LjubljanaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07734389 | Genetic Assessment of Breast Cancer Risk in Women in the DORA Programme | recruiting | N/A | 291 | Institute of Oncology LjubljanaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07724028 | Neurovascular Bundle Stimulation During Robot-Assisted Radical Prostatectomy(NVB Stym-RARP) | enrolling by invitation | N/A | 20 | University Medical Centre LjubljanaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07716124 | Use of AlignRT System During Stereotactic Radiosurgery | completed | N/A | 20 | Institute of Oncology LjubljanaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03466957 | Individual Approach in Gynecological Cancer Brachytherapy | active not recruiting | N/A | 50 | Institute of Oncology LjubljanaOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07701408 | ctDNA and TEP Levels in Colon Cancer | not yet recruiting | N/A | 80 | Institute of Oncology LjubljanaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | active not recruiting | Phase 3 | 382 | Hoffmann-La RocheINDUSTRY | 32 | Jul 10, 2026 | clinicaltrials |
| NCT07404527 | Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery | active not recruiting | N/A | 85 | Institute of Oncology LjubljanaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03591510 | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | active not recruiting | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 9, 2026 | clinicaltrials |
| NCT05054959 | Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence(ICONA) | active not recruiting | Phase 2 | 62 | Institute of Oncology LjubljanaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07684846 | Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer(TLPPROC) | completed | N/A | 33 | University Medical Centre LjubljanaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02834884 | SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access(SPECTA) | recruiting | — | 4,975 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 20 | Jun 24, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT07198945 | Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection(STARLING) | enrolling by invitation | N/A | 546 | Indiana UniversityOTHER | 3 | Jun 17, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT07630948 | Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer(riboADHERE) | not yet recruiting | Phase 4 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jun 4, 2026 | clinicaltrials |
| NCT07627022 | Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer(APPAREL) | not yet recruiting | N/A | 32 | University Hospital Schleswig-HolsteinOTHER | 4 | Jun 4, 2026 | clinicaltrials |
| NCT07380815 | Physical Activity During Radiation Therapy for Lung Cancer(APART-LUNG) | completed | — | 20 | University Hospital Schleswig-HolsteinOTHER | 4 | Jun 2, 2026 | clinicaltrials |
| NCT04529122 | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test | completed | — | 7,864 | Hoffmann-La RocheINDUSTRY | 32 | May 27, 2026 | clinicaltrials |
| NCT07405307 | Sarcopenia Risk Screening in Patients With Gastrointestinal Cancer Using SARC-F | completed | — | 44 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | active not recruiting | Phase 3 | 418 | Day One Biopharmaceuticals, Inc.INDUSTRY | 30 | May 14, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT01558921 | Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial(RAPIDO) | active not recruiting | Phase 3 | 920 | University Medical Center GroningenOTHER | 7 | May 1, 2026 | clinicaltrials |
| NCT05607888 | Prospective Study of Sinonasal and Skull-base Tumours Management(Sinonasal_Tu) | recruiting | — | 120 | University Medical Centre LjubljanaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07540650 | Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers(pRevenT) | not yet recruiting | Phase 2 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06856902 | BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe(BEAMER) | recruiting | N/A | 3,100 | Technical University of MadridOTHER | 8 | Apr 1, 2026 | clinicaltrials |
| NCT04281290 | Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)(PanECT) | active not recruiting | N/A | 10 | University Medical Centre LjubljanaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT07457255 | Late Endocrine and Metabolic Consequences After Childhood Brain Tumor Treatment | completed | N/A | 12 | Institute of Oncology LjubljanaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06650423 | Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer(ONCO-Adher) | recruiting | — | 319 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
Data updated 20 hours agoSource updated unknownsource: clinicaltrials